DRACO
DRACO (Double-stranded RNA Activated Caspase Oligomerizer) is an experimental antiviral therapeutic approach designed to target and eliminate cells infected by viruses. The concept was developed by researchers at the Massachusetts Institute of Technology (MIT) and aims to provide a broad-spectrum antiviral treatment.
Mechanism of Action[edit]
DRACO works by combining elements of the body's natural defense mechanisms against viral infections. It utilizes a protein that can detect the presence of double-stranded RNA (dsRNA), a molecular pattern associated with viral infections. Upon detection of dsRNA, DRACO triggers apoptosis, or programmed cell death, in the infected cell, thereby preventing the virus from replicating and spreading to other cells. The key components of DRACO include:
- A dsRNA-binding domain that recognizes and binds to dsRNA.
- A caspase recruitment domain (CARD) that activates the apoptotic pathway.
Development and Research[edit]
The initial development of DRACO was led by Dr. Todd Rider at MIT. Early studies demonstrated that DRACO could effectively target and kill cells infected by a wide range of viruses, including influenza, dengue virus, and rhinovirus. These studies were conducted in vitro (in cell cultures) and in vivo (in animal models).
Potential Applications[edit]
DRACO has the potential to be developed into a treatment for various viral infections, including:
Challenges and Future Directions[edit]
Despite its promising potential, DRACO faces several challenges before it can be used as a therapeutic in humans. These challenges include:
- Ensuring the specificity of DRACO to avoid off-target effects and damage to healthy cells.
- Optimizing delivery methods to effectively target infected cells in the human body.
- Conducting extensive clinical trials to establish safety and efficacy in humans.
Related Pages[edit]
See Also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
